BMC 128
Alternative Names: BMC-128; LS-LBP-002Latest Information Update: 09 Jun 2026
At a glance
- Originator Biomica
- Class Antineoplastics; Bacteria; Immunotherapies
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma
Most Recent Events
- 02 Jun 2026 Efficacy, adverse event and pharmacodynamic data from data from a phase I trial in Solid tumours released by Evogene
- 02 Jun 2026 Biomica completes a phase I trial in Malignant melanoma, Non-small cell lung cancer and Renal cell carcinoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Israel (PO) (NCT05354102)
- 04 Feb 2026 Evogene plans to advance regulatory filings in China and the United States for commercialization